Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 181

1.

Comparison of injectable anticoagulants for thromboprophylaxis after cancer-related surgery.

Changolkar A, Menditto L, Shah M, Puto K, Farrelly E.

Am J Health Syst Pharm. 2014 Apr 1;71(7):562-9. doi: 10.2146/ajhp120711.

PMID:
24644116
2.

Comparison of cost, effectiveness, and safety of injectable anticoagulants used for thromboprophylaxis after orthopedic surgery.

Shorr AF, Sarnes MW, Peeples PJ, Stanford RH, Happe LE, Farrelly E.

Am J Health Syst Pharm. 2007 Nov 15;64(22):2349-55.

PMID:
17989444
3.

Cost and occurrence of thrombocytopenia in patients receiving venous thromboembolism prophylaxis following major orthopaedic surgeries.

Happe LE, Farrelly EM, Stanford RH, Sarnes MW.

J Thromb Thrombolysis. 2008 Oct;26(2):125-31. Epub 2007 Nov 24.

PMID:
18034323
4.

Venous thromboembolism after orthopedic surgery: implications of the choice for prophylaxis.

Shorr AF, Kwong LM, Sarnes M, Happe L, Farrelly E, Mody-Patel N.

Thromb Res. 2007;121(1):17-24. Epub 2007 Apr 20.

PMID:
17449088
5.

Economic and clinical evaluation of fondaparinux vs. enoxaparin for thromboprophylaxis following general surgery.

Farias-Eisner R, Horblyuk R, Franklin M, Lunacsek OE, Happe LE.

Curr Med Res Opin. 2009 May;25(5):1081-7. doi: 10.1185/03007990902837117 .

PMID:
19298219
6.

Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.

Kanaan AO, Silva MA, Donovan JL, Roy T, Al-Homsi AS.

Clin Ther. 2007 Nov;29(11):2395-405. Review.

PMID:
18158080
7.

Efficacy and safety of venous thromboembolism prophylaxis with fondaparinux or low molecular weight heparin in a large cohort of consecutive patients undergoing major orthopaedic surgery - findings from the ORTHO-TEP registry.

Donath L, Lützner J, Werth S, Kuhlisch E, Hartmann A, Günther KP, Weiss N, Beyer-Westendorf J.

Br J Clin Pharmacol. 2012 Dec;74(6):947-58. doi: 10.1111/j.1365-2125.2012.04302.x.

8.

Comparative effectiveness of dalteparin and enoxaparin in a hospital setting.

Carson W, Schilling B, Simons WR, Parks C, Choe Y, Faria C, Powers A.

J Pharm Pract. 2012 Apr;25(2):180-9. doi: 10.1177/0897190011418514. Epub 2011 Oct 10.

PMID:
21987527
9.

Venous thromboembolism after total joint arthroplasty: results from a Japanese multicenter cohort study.

Migita K, Bito S, Nakamura M, Miyata S, Saito M, Kakizaki H, Nakayama Y, Matsusita T, Furuichi I, Sasazaki Y, Tanaka T, Yoshida M, Kaneko H, Abe I, Mine T, Ihara K, Kuratsu S, Saisho K, Miyahara H, Segata T, Nakagawa Y, Kamei M, Torigoshi T, Motokawa S.

Arthritis Res Ther. 2014 Jul 21;16(4):R154. doi: 10.1186/ar4616.

10.

Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients.

Fowler RA, Mittmann N, Geerts W, Heels-Ansdell D, Gould MK, Guyatt G, Krahn M, Finfer S, Pinto R, Chan B, Ormanidhi O, Arabi Y, Qushmaq I, Rocha MG, Dodek P, McIntyre L, Hall R, Ferguson ND, Mehta S, Marshall JC, Doig CJ, Muscedere J, Jacka MJ, Klinger JR, Vlahakis N, Orford N, Seppelt I, Skrobik YK, Sud S, Cade JF, Cooper J, Cook D; Canadian Critical Care Trials Group.; Australia and New Zealand Intensive Care Society Clinical Trials Group..

JAMA. 2014 Nov 26;312(20):2135-45. doi: 10.1001/jama.2014.15101.

PMID:
25362228
11.

Comparison of the two-year outcomes and costs of prophylaxis in medical patients at risk of venous thromboembolism.

Deitelzweig SB, Becker R, Lin J, Benner J.

Thromb Haemost. 2008 Nov;100(5):810-20.

PMID:
18989525
12.

Economic impact of enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in patients with acute ischemic stroke: a hospital perspective of the PREVAIL trial.

Pineo G, Lin J, Stern L, Subrahmanian T, Annemans L.

J Hosp Med. 2012 Mar;7(3):176-82. doi: 10.1002/jhm.968. Epub 2011 Nov 4.

PMID:
22058011
13.

Initiative to improve thromboprophylactic enoxaparin exposure in hospitalized patients with renal impairment.

Elsaid KA, Collins CM.

Am J Health Syst Pharm. 2012 Mar 1;69(5):390-6. doi: 10.2146/ajhp110319.

PMID:
22345418
14.

Clinical and economic outcomes in patients at risk of venous thromboembolism receiving appropriate enoxaparin or unfractionated heparin prophylaxis.

Amin AN, Lin J, Lenhart G, Schulman KL.

Thromb Haemost. 2009 Aug;102(2):321-6. doi: 10.1160/TH09-03-0147.

PMID:
19652883
15.

Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.

Akl EA, Rohilla S, Barba M, Sperati F, Terrenato I, Muti P, Schünemann HJ.

Cochrane Database Syst Rev. 2008 Jan 23;(1):CD006649. doi: 10.1002/14651858.CD006649.pub2. Review. Update in: Cochrane Database Syst Rev. 2011;(2):CD006649.

PMID:
18254108
16.

Safety of venous thromboembolism prophylaxis with fondaparinux in ischemic stroke.

Hackett CT, Ramanathan RS, Malhotra K, Quigley MR, Kelly KM, Tian M, Protetch J, Wong C, Wright DG, Tayal AH.

Thromb Res. 2015 Feb;135(2):249-54. doi: 10.1016/j.thromres.2014.11.041. Epub 2014 Dec 13.

17.
18.

Efficacy and safety of rivaroxaban or fondaparinux thromboprophylaxis in major orthopedic surgery: findings from the ORTHO-TEP registry.

Beyer-Westendorf J, Lützner J, Donath L, Radke OC, Kuhlisch E, Hartmann A, Weiss N, Werth S.

J Thromb Haemost. 2012 Oct;10(10):2045-52. doi: 10.1111/j.1538-7836.2012.04877.x.

19.

Routine use of fondaparinux in acute coronary syndromes: a 2-year multicenter experience.

Schiele F, Meneveau N, Seronde MF, Descotes-Genon V, Dutheil J, Chopard R, Ecarnot F, Bassand JP; Reseau de Cardiologie de Franche Comte..

Am Heart J. 2010 Feb;159(2):190-8. doi: 10.1016/j.ahj.2009.11.003.

PMID:
20152216
20.

The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery.

Gordois A, Posnett J, Borris L, Bossuyt P, Jönsson B, Levy E, de Pouvourville G.

J Thromb Haemost. 2003 Oct;1(10):2167-74.

Supplemental Content

Support Center